Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor: (hereinafter referred to as Compound A) for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, in particular hyperlipidemia or mixed dyslipidemia. A further aspect of the present invention relates to a pharmaceutical composition for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, wherein the composition comprises a therapeutically effective amount of said Compound A CETP inhibitor.
1. A solid, oral pharmaceutical composition, comprising 5 to 10 mg of compound A:
or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, wherein the composition is formulated for once a day administration.
2. The pharmaceutical composition according to claim 1 , comprising 5 mg or 10 mg of Compound A.
3. The pharmaceutical composition according to claim 1 , wherein the composition is formulated as a tablet or capsule.
4. The pharmaceutical composition according to claim 1 , comprising a salt of Compound A, wherein the salt is a calcium, potassium or sodium salt.
5. The pharmaceutical composition according to claim 1 , comprising 5 mg of Compound A.
6. The pharmaceutical composition according to claim 1 , comprising 10 mg of Compound A.